ArticleAnalytical and bioanalytical chemistry2025
Limitations of boronate affinity chromatography for the specific enrichment of fructose-derived early glycation products in protein analytics.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Protein glycation, or non-enzymatic glycosylation, refers to the reaction of reducing sugars with amino groups in proteins to form Amadori and Heyns products for aldoses (e.g., glucose) and ketoses (e.g., fructose), respectively. While Amadori peptides have been well studied after enrichment by boronate affinity chromatography (BAC), it is often assumed that BAC also enriches the isomeric Heyns peptides, although the binding of Heyns rearrangement products seems unlikely due to the very low content of 1,2- and 1,3-cis-diols in their dominant tautomeric forms. For seven different tryptic peptide sequences derived from human plasma digests, we showed that the synthetic glucose-modified Amadori peptides can be enriched by BAC with high recovery rates, while the corresponding fructose-modified Heyns peptides did not bind, independent of the buffers and pH used. Reduction of the carbonyl groups with borohydride, yielding the corresponding hexitol-modified peptides, allowed enrichment of both the former Amadori and, more importantly, Heyns peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.